Startup profile for Galvanize Therapeutics: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Galvanize Therapeutics funding, valuation and investors

US medical-device company commercializing pulsed electric field instruments for soft-tissue ablation, while investigating chronic-lung and oncology applications.

Verified company research · funding, investors and latest developments

Keep track of Galvanize Therapeutics

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series D

$130M · November 16, 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$330M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

growth · Redwood City, California, United States

Investors in latest funding

Lead: HealthQuest Capital

Other: Olympus Innovation Ventures , Braidwell LP , Sofinnova Partners , Norwest

Sources: latest funding · prnewswire.com Last verified: 2026-11-16

Overview

Galvanize Therapeutics develops medical devices that use high-voltage, short-duration pulsed electric fields (PEF) to ablate soft tissue, rather than relying primarily on heat. Its FDA-cleared Aliya and Aliya EX surgical platforms are used by specialist physicians; it is also developing RheOx for chronic bronchitis. The September 2022 merger brought Gala Therapeutics, Galaxy Medical and Galvanize together.

On November 16, 2026 the company announced a closed, HealthQuest-led $130M Series D. Separate primary releases establish $100M Series B in 2022 and $100M Series C in 2025. Across these three identified rounds the disclosed sum is $330M, not necessarily lifetime financing. Product pricing, company revenue and the 2026 valuation have not been disclosed.

FDA 510(k) clearance for surgical ablation of soft tissue is not a disease-specific cancer treatment approval.

Why Galvanize Therapeutics is interesting

Galvanize announced a CLOSED $130M Series D on November 16, 2026, led by HealthQuest Capital. Unlike a purely preclinical biotech, its Aliya system is marketed under FDA soft-tissue-ablation 510(k) clearances. The disease-specific benefit and immune-effect hypotheses should not be confused with that clearance. The issuer reports over 4,000 procedures and over 300 PROPEL-registry enrollments, not 4,000 controlled-trial successes.

Product & use cases

For a surgical/interventional specialist: assess whether soft-tissue ablation is appropriate; obtain informed consent and select an anatomical target using clinical imaging and the indicated procedure; choose the Aliya EX pulse generator and compatible Aliya needle/electrode or INUMI Flex delivery tool; place the applicator during an endoscopic or percutaneous procedure following the approved IFU; deliver controlled electrical pulses locally and conduct follow-up monitoring. This is a documentation-derived illustrative clinical workflow, NOT hands-on testing or patient guidance. Galvanize does not disclose hospitals' equipment, disposables or reimbursement prices. FDA clearance covers surgical ablation of soft tissue only, and its own labeling disclaims established disease-specific treatment or immune-response benefit.

  • Hospital use of FDA 510(k)-cleared Aliya/EX system for surgical ablation of soft tissue by trained physicians.
  • PROPEL post-market registry and research tracking clinical use; registry enrollment is observational evidence, not randomized proof of cancer outcomes.
  • Research/clinical development of RheOx PEF technology for chronic-bronchitis symptoms; applicable jurisdictions and status require separate device-specific review.

Key facts

  • Closed $130M Series D announced 2026-11-16, led by HealthQuest Capital, with Olympus Innovation Ventures and Braidwell as new investors.
  • Earlier original-company releases disclose $100M Series B (September 2022) and $100M Series C (September 2025). Three documented rounds total $330M; undisclosed earlier funding is excluded.
  • Issuer reports over 4,000 Aliya procedures and more than 300 enrolled in PROPEL registry; counts are not efficacy endpoints or audited sales.
  • FDA 510(k) K253826 cleared Aliya EX May 7, 2026 for surgical ablation of soft tissue, not for treatment/cure of a specified disease.
  • Immune activation and disease-specific oncology benefit remain investigational; patient-benefit effectiveness has not been established.

Funding history (newest first)

Series D

2026-11-16 $130M
  • HealthQuest Capital (lead)
  • Olympus Innovation Ventures (participant)
  • Braidwell LP (participant)
  • Sofinnova Partners (participant)
  • Norwest (participant)

Source: Read source · prnewswire.com

Series C

2025-09-03 $100M
  • Sofinnova Partners (lead)
  • Norwest (participant)
  • Elevage Medical Technologies (participant)
  • Ally Bridge Group (participant)

Source: Read source · prnewswire.com

Series B

2022-09-15 $100M
  • Fidelity Management & Research Company (lead)
  • ATP (Apple Tree Partners) (participant)
  • Intuitive Surgical (participant)
  • Gilmartin Capital (participant)

Source: Read source · prnewswire.com

Competitive landscape

Edge: The non-thermal PEF mechanism can preserve some surrounding structural tissue and differs operationally from radiofrequency/microwave/cryogenic thermal ablation, according to Galvanize's cited materials. The company's claims about predictability, immune stimulation or clinical superiority require comparative evidence; do not imply established patient-benefit improvement.

  • AngioDynamics NanoKnife direct

    Another irreversible-electroporation soft-tissue ablation technology; indications, electrodes and evidence differ.

  • Radiofrequency ablation systems alternative

    Established heat-based ablation modality; thermal injury and heat-sink considerations differ by anatomy.

  • Microwave ablation devices alternative

    Heat-based ablation alternative with different procedural and anatomical tradeoffs.

  • Cryoablation systems alternative

    Cold-based surgical ablation alternative; clinical selection is indication-specific.

Market / IPO context

Editorial / static context — not a live quote.

FAQs about Galvanize Therapeutics

Practical answers founders, operators, and investors typically search for.

No disease-specific cancer treatment approval is established by the referenced clearances. FDA 510(k) has cleared the Aliya system for surgical ablation of soft tissue; clinical outcomes and immune-response benefits remain under study.
Galvanize's November 16 original issuer release says the $130M Series D is closed and led by HealthQuest Capital. The amount is the Series D, not the sum of earlier rounds.
The November 2026 issuer release does not disclose the Series D valuation, device capital cost, consumables pricing or hospital reimbursement arrangements.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.